ResMed Inc.'s Global General Counsel, Rider Michael J, sold 50 shares of the company’s common stock for $13,000 on February 4, 2026, under a Rule 10b5-1 plan. Despite this insider sale, analysts maintain a positive outlook on ResMed following its strong Q2 fiscal 2026 performance, where it exceeded EPS forecasts and matched revenue expectations. The stock is currently trading slightly below its Fair Value estimate according to InvestingPro analysis.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Resmed: global general counsel Rider sells $13,000 in stock
ResMed Inc.'s Global General Counsel, Rider Michael J, sold 50 shares of the company’s common stock for $13,000 on February 4, 2026, under a Rule 10b5-1 plan. Despite this insider sale, analysts maintain a positive outlook on ResMed following its strong Q2 fiscal 2026 performance, where it exceeded EPS forecasts and matched revenue expectations. The stock is currently trading slightly below its Fair Value estimate according to InvestingPro analysis.